Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy

The findings of this five-year study by the Diabetic Retinopathy Clinical Research Network support either anti-VEGF therapy or panretinal photocoagulation as viable treatment for patients with proliferative diabetic retinopathy.

“Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy”
A Randomized Clinical Trial

JAMA Ophthalmol 136, Vol 10:1138-1148, Oct 2018
Jeffrey G. Gross, MD et al

Full Paper: Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy

Download (317K PDF)